September 01, 2017

Government Funding of Pharmaceutical Research and Development

Greg Vogel, Archer Attorneys at Law, Haddonfield, NJ

All companies have to make difficult choices prioritizing objectives. In addition to other factors, pharmaceutical companies must also consider the potential of any given clinical development plan years before success or failure can be determined. Bringing a product to market is costly, not only in terms of direct research and development costs, but also the opportunity costs of potential products that get deprioritized in a company’s cost-benefit analyses. These cost-benefit analyses have real world consequences - it is not an understatement to say that in the pharmaceutical field, a company’s decisions, successes, and failures directly affect the lives of its end users.

Premium Content For:
  • Health Law Section
    • ABA Health eSource
Join - Now